, Tracking Stock Market Picks
Enter Symbol:
Rating: REGN
Buy $660
up 14.00 %

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reiterated to Buy with price target $660 by Argus

Thursday,  Aug 6, 2015  2:25 PM ET by Dave Ficere

Argus reiterated Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Buy with price target $660. Previously Argus rated Buy with price target $560 Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) on 05/20/2015, when the stock price was $514.19. Since then, Regeneron Pharmaceuticals, Inc.'s stock price has gained 14% as of 08/06/2015's recent price of $584.10.
If you would have followed the previous Argus's recommendation on REGN, you would have gained 14% of your investment in 78 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy